Search results for "Blood coagulation factors"

showing 10 items of 28 documents

CD36-fibrin interaction propagates FXI-dependent thrombin generation of human platelets.

2019

Thrombin converts fibrinogen to fibrin and activates blood and vascular cells in thrombo-inflammatory diseases. Platelets are amplifiers of thrombin formation when activated by leukocyte- and vascular cell-derived thrombin. CD36 on platelets acts as sensitizer for molecules with damage-associated molecular patterns, thereby increasing platelet reactivity. Here, we investigated the role of CD36 in thrombin-generation on human platelets, including selected patients with advanced chronic kidney disease (CKD). Platelets deficient in CD36 or blocked by anti-CD36 antibody FA6.152 showed impaired thrombin generation triggered by thrombin in calibrated automated thrombography. Using platelets with …

0301 basic medicineBlood PlateletsCD36 AntigensCD36InflammationFibrinogenBiochemistryFibrin03 medical and health sciences0302 clinical medicineThrombinBlocking antibodyGeneticsmedicineHumansPlateletRenal Insufficiency ChronicMolecular BiologyFactor XIFibrinbiologyChemistryCell adhesion moleculeThrombinPlatelet ActivationBlood Coagulation FactorsCell biology030104 developmental biologybiology.proteinmedicine.symptom030217 neurology & neurosurgerycirculatory and respiratory physiologyBiotechnologymedicine.drugFASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES
researchProduct

sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor

2020

Mutations in Factor XII, plasminogen gene, angiopoietin-1 gene and kininogen 1 gene have been found in some patients with hereditary angioedema with normal C1 inhibitor (HAE-nl-C1inh), but the underlying disease mechanisms remain unclear. Additionally, there are no accepted biomarkers for this disease. Because the contact system has been implicated in hereditary angioedema with C1 inhibitor deficiency (HAE-C1inh), we studied the fragmentation patterns of serum glycoprotein 120 (sgp120), a protein that is highly susceptible to cleavage by kallikrein, in 31 HAE-C1inh and 13 HAE-nl-C1inh patient plasma samples. Compared to normal controls, the majority of plasma samples from patients with HAE-…

0301 basic medicineImmunologyProteinase Inhibitory Proteins SecretoryCleavage (embryo)C1-inhibitor03 medical and health sciences0302 clinical medicinemedicineHumansKaolinComplement ActivationMolecular BiologyGenechemistry.chemical_classificationChromatographyFactor XIIbiologyChemistryAngioedemas HereditaryPlasminogenKallikreinmedicine.diseaseMolecular biologyBlood Coagulation FactorsPeptide Fragments030104 developmental biologyFactor XIIProteolysisHereditary angioedemabiology.proteinBiomarker (medicine)KallikreinsGlycoproteinComplement C1 Inhibitor ProteinPlasticsBiomarkers030215 immunologyMolecular Immunology
researchProduct

Safety of prothrombin complex concentrate in healthy subjects

2017

Keywords: anticoagulants; prothrombin complex concentrate; thrombosis; reversal; meta-analysis; bleeding disorders

0301 basic medicinemedicine.medical_specialtybusiness.industryHealthy subjectsHemorrhageHematology030204 cardiovascular system & hematologymedicine.diseaseThrombosisProthrombin complex concentrateBlood Coagulation FactorsHealthy Volunteers03 medical and health sciences030104 developmental biology0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansbusinessBlood Coagulationhuman activitiescirculatory and respiratory physiologymedicine.drug
researchProduct

The important impact of dental care on haemostatic treatment burden in patients with mild haemophilia

2022

Background: Mild haemophilia (MH) is mainly characterized by haemorrhages secondary to surgery/invasive procedures or trauma. Haemostatic treatment in MH ranges from on demand to short prophylaxis according to the type of bleeding events and the basal clotting factor level. Oral surgery and dental extractions can represent a frequent haemostatic challenge in MH requiring appropriate treatment. However, only few studies on limited numbers of patients are available in the literature regarding the implications of dental management in patients with MH. Objectives: The purpose of the study was to evaluate the impact of dental care on the burden of haemostatic treatment in patients affected by MH…

AdultMaleAged 80 and overFactor VIIIAdolescentHemorrhageHematologyGeneral MedicineMiddle AgedHemophilia Amild haemophilia dental care FVIII FIX haemophilia treatmentHemostaticsAntifibrinolytic AgentsBlood Coagulation FactorsYoung AdultHumansDental CareGenetics (clinical)Aged
researchProduct

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Obesity, hypertension and atherosclerosis

1993

Hypertension and obesity are associated with an increased risk of clinical cardiovascular complications due to atherosclerosis. Moreover has been reported that hypertension may predispose to atheroma development. In the present review some common aspects to hypertension and atherosclerosis including smooth muscle cell proliferation, endothelial damage and intervention of growth factors have been analyzed. Additional data have to be provided to explain if the connections between hypertension and atherosclerosis could be considered two effects with one unknown cause. In addition some aspects related to obesity and atherosclerosis have been dissected. In particular we have reported our results…

AdultMaleSettore MED/09 - Medicina InternaArteriosclerosisMyocardial InfarctionLipidsSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareBlood Coagulation FactorsObesity hypertension atherosclerosisRisk FactorsHypertensionPrevalenceHumansFemaleObesity
researchProduct

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patient…

2008

We recommend prophylaxis in haemophilic children with an inhibitor as a way of preventing the musculoskeletal impairment that is likely to affect them. This approach has been used for children without inhibitors with excellent results. If prophylaxis is not feasible, we suggest that intensive on-demand treatment should be given. Two agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCC), are currently used to control haemostasis either for prophylaxis or intensive on-demand treatment. As it is recombinant, rFVIIa would seem more appropriate to be employed in children. aPCC could be used in adults, or in the event of an unsatisfactory response to rF…

AdultMalemedicine.medical_specialtyPediatricsTime FactorsEvidence-based practiceAdolescentFactor VIIaHemophilia AHaemophiliaFactor IXYoung AdultHemarthrosismedicineOrthopaedic proceduresHumansPain ManagementOrthopedic ProceduresChildIntensive care medicinePhysical Therapy ModalitiesGenetics (clinical)Randomized Controlled Trials as TopicRetrospective StudiesHaemophilic arthropathySynovitisBlood Coagulation Factor InhibitorsCoagulantsbusiness.industryMusculoskeletal impairmentHematologyGeneral MedicinePerioperativemedicine.diseaseSkeletal maturityBlood Coagulation FactorsRecombinant ProteinsCartilageTreatment OutcomeChild PreschoolPractice Guidelines as TopicbusinessPROTHROMBIN COMPLEXHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct